Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult;Guía para el diagnóstico y tratamiento de la insuficiencia suprarrenal en el adulto

Endocrinologia y Nutricion

Volumn 61, Issue S1, 2014, Pages 1-35

  Miguel Novoa, Paz de ^a   Vela, Elena Torres ^b   García, Nuria Palacios ^c   Rodríguez, Manuela Moreira ^d   Guerras, Icíar Solache ^e   Martínez de Salinas Santamaría, María de los Ángeles ^f   Masó, Anna Aulinas ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d Gerencia Regional de Salud de Castilla y León   (Spain)

^e Servicio de Endocrinología y Nutrición Complexo Hospitalario Universitario de Ourense   (Spain)

^f HOSPITAL SAN PEDRO   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adrenal insufficiency; Diagnosis; Treatment

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORTICOTROPIN; ETOMIDATE; FLUDROCORTISONE; GLUCAGON; GLUCOCORTICOID; GLUCOSE; HORMONE; HORMONE ANTIBODY; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; LIPID; LITHIUM; METYRAPONE; MINERALOCORTICOID; MITOTANE; PHENYTOIN; POTASSIUM; PRASTERONE; PROGESTERONE; SEX HORMONE; SODIUM; STEROID; TESTOSTERONE; TETRACOSACTIDE;

ACNE; ADENOMA; ADRENAL CORTEX; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADRENOLEUKODYSTROPHY; ADULT DISEASE; ALDOSTERONE RELEASE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BODY COMPOSITION; BONE DENSITY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CATARACT; CHEMICAL PARAMETERS; CIRCADIAN RHYTHM; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN DEFICIENCY; CORTICOTROPIN RELEASE; CORTICOTROPIN TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIARRHEA; DRUG CONTRAINDICATION; ELECTROLYTE BLOOD LEVEL; ELEVATED BLOOD PRESSURE; ENDOCRINE FUNCTION TEST; ENDOCRINE SURGERY; EXERCISE; GENE MUTATION; GENETIC SCREENING; GLAUCOMA; GOLD STANDARD; HAIR LOSS; HEAD INJURY; HIRSUTISM; HORMONE DEFICIENCY; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERANDROGENISM; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; HYPOPHYSIS ADENOMA; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOVOLEMIA; IMMUNE SYSTEM; INSULIN HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA TEST; LABOR MANAGEMENT; LONG TERM CARE; MEASUREMENT ACCURACY; NEWBORN MONITORING; NONHUMAN; OILY SKIN; OSTEOPOROSIS; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA RENIN ACTIVITY; POSITIONAL DIZZINESS; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREGNANCY; PROVOCATION TEST; QUALITY OF LIFE; RADIODIAGNOSIS; SCALP PRURITUS; SENSITIVITY AND SPECIFICITY; SEXUALITY; STRESS; SUBSTITUTION THERAPY; SWEAT GLAND DISEASE; TREATMENT WITHDRAWAL; TROPIC CLIMATE; URINE LEVEL; VACCINATION; ADULT; ALGORITHM;

ADRENAL INSUFFICIENCY; ADULT; ALGORITHMS; HUMANS;

EID: 84905861543     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(14)73526-0     Document Type: Article

References (171)

1. Addison T. On the constitutional and local effects of disease of the supra-renal capsules. London: Highley; 1855.
2. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J. 1997;73:286-8.
3. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab. 1999;84:1762.
4. Erichsen MM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009;94:4882-90.
5. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361: 1881-93.
6. Oelkers W. Adrenal insufficiency. N Engl J Med. 1996;335: 1206-12.
7. Hägg E, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf). 1987;26:221-6.
8. Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998;83:2350-4.
9. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003;88:4193-8.
10. Le Roux CW, Meeran K, Alaghband-Zadeh J. Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment? Ann Clin Biochem. 2002;39:148-50.
11. Marcus-Perlman Y, Tordjman K, Greenman Y, Limor R, Shenkerman G, Osher E, et al. Low-dose ACTH (1mcg) salivary test: a potential alternative to the classical blood test. Clin Endocrinol (Oxf). 2006;64:215-8.
12. Simunková K, Stárka L, Hill M, Kríz L, Hampl R, Vondra K. Comparison of total and salivary cortisol in a low-dose ACTH (Synacthen) test: influence of three-month oral contraceptives administration to healthy women. Physiol Res. 2008;Suppl 1:S193-9.
13. Contreras LN, Arregger AL, Persi GG, González NS, Cardoso EM. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin. Clin Endocrinol (Oxf). 2004;61:675-82.
14. Ceccato F, Barbot M, Zilio M, Ferasin S, Occhi G, Daniele A, et al. Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma and adrenal insufficiency. Eur J Endocrinol.2013;169:31-6.
15. Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, et al. Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol. 2012;166:613-8.
16. Sonw K, Jiang NS, Kao PC, Scheithaver BW. Biochemical evaluation of adrenal dysfunction: the laboratory perspective. Mayo Clin Proc. 1992;67:1055-65.
17. Nieman LK. Insulin-induced hypoglycemia test. Up ToDate, 2013.
18. Reimondo G, Bovio S, Allasino B, Terzolo A. Secondary hypoadrenalism. Pituitary. 2008;11:147-54.
19. Dorin R, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2004;140:315.
20. Gleeson HK, Walker BR, Seckl JR, Padfield PL. Ten years on: safety of short synacthen tests in assessing adrenocorticotropin deficiency in clinical practice. J Clin Endocrinol Metab. 2003;88:2106-11.
21. Ferrante E, Morelli V, Giavoli C, Mantovani G, Varrua E, Sala E, et al. Is the 250 mcg ACTH test a useful tool for the diagnosis of central hypoadrenalism in adult patients with pituitary disorders? Hormones. 2012;11:428-35.
22. Abdu TAM, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short Synacthen test (1mcg), the conventional dose short synacthen test (250 mcg) and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab. 1999;84:838-43.
23. Dökmetas HS, Colak R, Kelestimur F, Selçuklu A, ünlühizarci K, Bayram F. A comparison between the 1-mcg adrenocorticotropin (ACTH) test, the short ACTH (250 mcg) test, and the insulin tolerance test in the assessment of hypothalamopituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab. 2000;85:3713-9.
24. Tordjman K, Jaffe A, Trostanetsky Y, Greenman Y, Limor R, Stern N. Low-dose (1mcg) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamopituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 mcg) test. Clin Endocrinol (Oxf). 2000;52:633-40.
25. Kauzlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, et al. Corticotropin Test for hypothalamicpituitary-adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008;93:4245-53.
26. Suliman AM, Smith T, Labib M, Fiad TM, Mckenna TJ. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf). 2002;56:533-9.
27. Karaca Z, Lale A, Tanriverdi F, Kula M, Unluhizarci K, Kelestimur F. The comparison of low and standard dose ACTH and glucagon stimulation test in the evaluation of hypothalamo-pituitary-adrenal axis in healthy adults. Pituitary. 2011;14:134-40.
28. Yuen KC, Biller BM, Katznelson L, Rhoads S, Gurel MH, Chu O, et al. Clinical characteristics, timing of peak responses and safety aspect os two dosing regiments os the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. Pituitary. 2013;16:220-30.
29. Cegla J, Jones B, Seyani L, PapadoulouD, Wynne K, Martin NM, et al. Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism. Clin Endocrinol (Oxf). 2013;78:738-42.
30. Schindlhelm RK, Van der Leur JJ, Rondeel JM. Salivary cortisol as an alternative for serum cortisol in the low-dose adrenocorticotropic hormone stimulation test? J Endocrinol Invest. 2010;33:92-5.
31. Dickstein G, Shechner C, Nicholson WE, Rosner I, Shen-Orr Z, Adawi F, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991;72:773-8.
32. Karaca Z, Tanriverdi F, Atmaca H, Gokce C, Elbuken G, Selcuklu A, et al. Can basal cortisol measurement be an alternative to the insulin tolerance test in the assessment of the hypothalamic-pituitary-adrenal axis before and after pituitary surgery? Eur J Endocrinol. 2010;163:377-82.
33. Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ. Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation. J Neurosurg. 2009;111:540-4.
34. Falorni A, Laureti S, Nikoskhov A, Pcchio ML, Hallengren B, Vandewalle CL, et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. Clin Exp Inmunol.1997;107:341-6.
35. Guo YK, Yang ZG, Li Y, Ma ES, Deng YP, Min PQ, et al. Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation. Eur J Radiol. 2007; 62:126-31.
36. Wang L, Yang J. Tuberculous Addison's disease mimics malignancy in FDG-PET images. Intern Med. 2008;47:1755-6.
37. Roundaut N, Malecot JM, Dupont E, Boussion S, Visvikis D, Doucet L, et al. Adrenal tuberculosis revealed by FDG PET. Clin Nucl Med. 2008;33:821-3.
38. Manganaro L, Al Ansari N, Barchetti F, Saldari M, Vitturini C, Glorioso M, et al. Bilateral adrenal hemorrhage in a patient with myelodysplastic syndrome: value of MRI in the differential diagnosis. Case Rep Radiol. 2013;2013:479836.
39. Ronghe MD, Barton J, Jardine PE, Crowne EC, Webster MH, Armitage M, et al. The importance of testing for adrenoleucodystrophy in males with idiopathic Addison's disease. Arch Dis Child. 2002;86:185-9.
40. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45: 100-10.
41. Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab. 1999;66:128-36.
42. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317:812-8.
43. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A. Long term control of hypercortisolism with fiuconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154:519-24.
44. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci. 1986;291:280-3.
45. Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicininduced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab. 1984;59:1204-6.
46. Lodish M, Stratakis C. NIH Public Access. Endocrine Reated Cancer. 2011;17:1-18.
47. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamuspituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29:501-3.
48. Tabarin A, Achermann JC, RecanD, Bex V, Bertagna X, Chirtin-Maitre S, et al. A novel mutation in DAX1 causes delayedonset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest. 2000;105: 321-8.
49. Fichna M, Fichna P, Gryczy??ska M, Walkowiak J, Zurawek M, Sowiński J. Screening for associated autoimmune disorders in Polish patients with Addison's disease. Endocrine. 2010;37:349-60.
50. Betterle C, Scarpa R, Garelli S, Morlin L, Lazzarotto F, Presotto F, et al. Addison's disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013;169:773-84.
51. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009;94:4882-90.
52. De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab. 2005;19:67-84.
53. Ozawa Y, Shishiba Y. Recovery from lymphocytic hypophysitis associated with painless thyroiditis: clinical implications of circulating antipituitary antibodies. Acta Endocrinol (Cophenh). 1993;128:493-8.
54. Wilson V, Mallipedhi A, Stephens JW, Redfern RM, Price DE. The causes of hypopituitarism in the absence of abnormal pituitary imaging. QJM. 2014;107:21-4.
55. Lewis AS, Courtney CH, Atkinson AB. All patients with "idiopathic" hypopituitarism should be screened for hemochromatosis. Pituitary. 2009;12:273-5.
56. Bottner A, Keller E, Kratzsch J, Stobbe H, Weigel JF, Keller A, et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab. 2004;89: 5256-65.
57. Furst DE, Saag KG. Glucocorticoid withdrawal. UpToDate. 2014.
58. Nieman LK. Pharmacologic use of glucocorticoids. UpToDate. 2013.
59. Lipworth BJ, Jackson CM. Effects of oral and inhaled corticosteroids on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1999;104(3 Pt 1):713-4.
60. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamuspituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29:501-3.
61. Jensen MD, Handwerger BS, Scheithauer BW, Carpenter PC, Mirakian R, Banks PM. Lymphocytic hypophysitis with isolated corticotropin deficiency. Ann Intern Med. 1986;105:200-3.
62. Kasperlik-Załuska AA, Czarnocka B, Czech W. Autoimmunity as the Most Frequent Cause of Idiopathic Secondary Adrenal Insufficiency: Report of 111 Cases. Autoinmunity. 2009;36: 155-9.
63. De Bellis A, Ruocco G, Battaglia M, Conte M, Coronella C, Tirelli G, et al. Immunological and clinical aspects of lymphocytic hypophysitis.Clin Sci (Lond). 2008;114:413-21.
64. Aimaretti G, Ambrosio MR, Di Somma C, Fusco A, Cannavò S, Gasperi M, et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf). 2004;61:320-6.
65. Hellman L, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42:912-7.
66. Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, Drouin J. Tpit determines alternate fates during pituitary cell differentiation. Genes Dev. 2003;17:738-47.
67. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19:155-7.
68. Debono M, Ross RJ. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009;160:719-29.
69. Erichsen MM, Løvas K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol. 2009;160:233-7.
70. Druce MR, Akker SA, Chew SL, Drake WM, Grossman AB. Morbidity in patients on long-term steroid replacement therapy. Clin Endocrinol (Oxf). 2010;72:564-6.
71. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91: 3954-61.
72. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301-42.
73. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab. 2006;91:4849-53.
74. Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008;69:697-704.
75. Björnsdottir S, Sääf M, Bensing S, Kämpe O, Michaëlsson K, Ludvigsson JF. Risk of hip fracture in Addison's disease: a population-based cohort study. J Intern Med. 2011;270: 87-195.
76. Jódar E, Valdepeñas MP, Martínez G, Jara A, Federico Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf). 2003;58:617-20.
77. Løvas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160:993-1002.
78. Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on lowdose glucocorticoid replacement therapy. J Clin Endocrinol Metab. 2012;97:85-92.
79. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007;92:3912-22.
80. Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol. 2008;159:811-7.
81. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency -a worldwide patient survey. BMC Endocr Disord. 2012;13:12-8.
82. Buckley TM, Schatzberg AF. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab. 2005;90:3106-14.
83. Klement J, Hubold C, Cords H, Oltmanns KM, Hallschmid M, Born J, et al. High-calorie glucose-rich food attenuates neuroglycopenic symptoms in patients with Addison's disease. J Clin Endocrinol Metab. 2010;95:522-8.
84. Løvas K, Curran S, Oksnes M, Husebye ES, Huppert FA, Chatterjee VK. Development of a disease-specific quality ofiife questionnaire in Addison's disease. J Clin Endocrinol Metab. 2010;95:545-51.
85. Øksnes M, Bensing S, Hulting AL, Kampe O, Hackemann A, Meyer G, et al. Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab. 2012;97:568-76.
86. Aulinas A, Casanueva F, Goñi F, Monereo S, Moreno B, Picó A, et al. Insufficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España. Endocrinol Nutr. 2013;60:136-43.
87. Falorrni A, Minarelli V, Morelli S. Therapy of adrenal insufficiency: an update. Endocrine. 2013;43:514-28.
88. Grossman A, Johannsson G, Quinkler M, Zelissen P. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013;169:165-75.
89. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012;76:21-25.
90. Reisch N, Arlt W. Fine tuning for quality of life: 21st century approach to treatment of Addison's disease. Endocrinol Metab Clin N Am. 2009;38:407-18.
91. Debono M, Ross RJ. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012? Clini Endocrinol (Oxf). 2013;78:659-64.
92. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:1059-67.
93. Disponible en: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Summary_for_the_public/ human/002185/WC500117640.pdf
94. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161:119-30.
95. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97: 473-81.
96. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94:1548-54.
97. Verma S, VanRyzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, et al. A pharmacokinetic and pharmacodynamic study of delayed-and extended-release hydrocortisone (ChronocortTM) vs. conventional hydrocortisone (CortefTM) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2010;72:441-7.
98. Løvas K, Husebye ES. Continuous subcutaneous hydro cortisone infusion in Addison's disease. Eur J Endocrinol. 2007;157: 109-12.
99. Disponible en: http://clinicaltrials.gov/show/NCT01063569
100. Nieman LK. Treatment of adrenal insufficiency in adults. 2013; UpToDate.
101. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insuffiency. Clin Endocrinol (Oxf). 2004;61: 367-75.
102. Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf). 2006;64:384-9.
103. Falorni A, Minarelli V, Morelli S. Therapy of adrenal insufficiency: an update. Endocrine. 2013;43:514-28.
104. Howlett TA. An assesment of optimal hidrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997;46:255-61.
105. Oelkers W, Buchen S, Diederich S, Krain J, Muhme S, Schöneshöfer M. Impaired renal 11 beta-oxidation of 9 alphafluorocortisol: an explanation for its mineralocorticoid potency. J Clin Endocrinol Metab. 1994;78:928-32.
106. Allolio B, Arlt W, Hahner S. DHEA: why, when, and how much-DHEA replacement in adrenal insufficiency. Ann Endocrinol (Paris). 2007;68:268-73.
107. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23: 167-79.
108. Salvatori R. Adrenal insufficiency. JAMA. 2005;294:2481-8.
109. Oki K, Yamane K. Therapies for adrenal insufficiency. Expert Opin Pharmacother. 2007;8:1283-91.
110. Arlt W. Adrenal insufficiency. Clin Med. 2008;8:211-5.
111. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23: 167-79.
112. Thompson DG, Mason AS, Goodwin FJ. Mineralocorticoid replacement in Addison's disease. Clin Endocrinol (Oxf). 1979; 10:499-506.
113. Cohen N, Gilbert R, Wirth A, Casley D, Jerums G. Atrial natriuretic peptide and plasma renin leveles in assessment of mineralcorticoid replacement in Addison disease. J Clin Endocrinol Metab. 1996;81:1411-5.
114. Oelkers W, L'age M. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement. Klin. Wochenschr. 1976;54:607-12.
115. Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 1992;75:259-64.
116. Smith SJ, MacGregor GA, Markandu ND, Bayliss J, Banks RA, Prentice MG, et al. Evidence that patients with Addison's disease are undertreated with fiudrocortisone. Lancet. 1984;1:11-4.
117. Jadoul M, Ferrant A. Mineralcorticoids in the management of primary adrenocortical insufficiency. J Endocrinol Invest. 1991;14:87-91.
118. Conn JW, Hinerman DL. Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies. Metabolism. 1977;26:1293-307.
119. Oelkers W, Bähr V. Effects of fiudrocortisone withdrawal on plasma angiotensina II, ACTH, vasopressin, and potassium in patients with Addison's disease. Acta Endocrinol (Copenh). 1987;115:325-30.
120. Morgan L, Broughton Pipkin F, Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol. 1996;28:1211-22.
121. Reid IA, Tu WH, Otsuka K, Assaykeen TA, Ganong WF. Studies concerning the regulation and importance of plasma angiotensinogen concentration in the dog. Endocrinology. 1973;93:107-14.
122. Flad TM, Conway JD, Cunningham SK, McKenna TJ. The role of plasma renin activity in evaluating the adequacy of mineralcorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf). 1996;45:529-34.
123. Belkien L, Exner P, Oelkers W. Active and inactive renin in primary and secondary adrenal insufficiency and during ACTH infusion. Acta Endocrinol (Copenh). 1983;102:265-70.
124. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2013; 98:2645-55.
125. Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjöld A, Hagenfeldt K, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007;92:110-6.
126. Cronin CC, Callaghan N, Kearney PJ, Murnaghan DJ, Shanahan F. Addison disease in patients treated with glucocorticoid therapy. Arch Intern Med. 1997;157:456-8.
127. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012;76:21-5.
128. Løvås K, Husebye ES. Replacement therapy for Addison's disease: recent developments. Expert Opin Investig Drugs. 2008;17:497-509.
129. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996;61: 166-71.
130. Altamura AC, Morganti A. Plasma renin activity in depressed patients treated with increasing doses of lithium carbonate. Psychopharmacologia. 1975;45:171-5.
131. Stewart PM, Atherden SM, Stewart SE, Whalley L, Edwards CR, Padfield PL. Lithium carbonate-a competitive aldosterone antagonist? Br J Psychiatry. 1988;153:205-7.
132. Stewart PM, Grieve J, Nairn IM, Padfield PL, Edwards CR. Lithium inhibits the action of fiudrocortisone on the kidney. Clin Endocrinol (Oxf). 1987;27:63-8.
133. Prentice M, Russell G. Lithium blocks the mineralocorticoid action of fludrocortisone in Addison's disease both for replacement and in the treatment of Addisonian crisis. Endocr Abstr. 2008;(15):P70.
134. Gómez-Herreros R, Gotor Sánchez-Luengo F, Del Valle-Villagrán J, Fernández-López I. Fludrocortisone resistance in a patient with Addison disease and bipolar disorder treated with lithium. Med Clin (Barc). 2007;128:397.
135. Krysiak R, Okopień B. Drug-induced exacerbation of hypoaldosteronism in autoimmune polyglandular syndrome type 2. Wiad Lek. 2012;65:239-42.
136. Allolio B, Arlt W, Hahner S. DHEA: why, when, and how much -DHEA replacement. Ann Endocrinol (Paris). 2007;68:268-73.
137. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000;85:4650-6.
138. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93:400-9.
139. Johannsson G, Burman P, Wirén L, Engström BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:2046-52.
140. Arlt W, Callies F, Van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehidroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341: 1013-20.
141. Dhatariya KK, Greenlund LJ, Bigelow ML, Thapa P, Oberg AL, Ford GC, et al. Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin Proc. 2008;83:1218-25.
142. Bilger M, Speraw S, LaFranchi SH, Hanna CE. Androgen replace ment in adolescents and young women with hypopituitarism. J Pediatr Endocrinol Metab. 2005;18: 355-62.
143. Christiansen JJ, Bruun JM, Christiansen JS, Jørgensen JO, Gravholt CH. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. Eur J Endocrinol. 2011;165:293-300.
144. Alkatib AA, Cosma M, Elamin MB, Erickson D, Swiglo BA, Erwin PJ, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676-81.
145. Løvås K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebø BG, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003;88:1112-8.
146. Brooke MA, Kalingag LA, Miraki-Moud F, Camacho-Hübner C, Maher KT, Walker DM, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab. 2006;91:3773-9.
147. Van Thiel SW, Romijn JA, Pereira AM, Biermasz NR, Ferdinand Roelfsema F, Van Hemert A, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor i in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab. 2005;90:3295-303.
148. Binder G, Weber S, Ehrismann M, Zaiser N, Meisner C, Ranke MB, et al; and the South German Working Group for Pediatric Endocrinology. Effeccts of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab. 2009;94:1182-90.
149. Mille KK, Biller BKM, Beauregard C, Lipman JG, Jones J, Schoenfeld D, et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2006;91:1683-90.
150. Libè R, Barbetta L, Dall'Asta C, Salvaggio F, Gala C, Beck-Peccoz P, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest. 2004;27: 736-41.
151. McHenry CM, Bell PM, Hunter SJ, Thompson CJ, Courtney CH, Ennis CN, et al. Effects of dehydroepiandrosterone sulphate (DHEAS) replacement on insulin action and quality of life in hypopituitary females: a double-blind, placebo-controlled study. Clin Endocrinol (Oxf). 2012;77:423-9.
152. Rice SP, Agarwal N, Bolusani H, Newcombe R, Scanlon MF, Ludgate M, et al. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab. 2009;94:1966-72.
153. Christiansen JJ, Andersen NH, Sørensen KE, Pedersen EM, Bennett P, Andersen M, et al. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clin Endocrinol (Oxf). 2007;66:426-33.
154. Dhatariya K, Bigelow ML, Nair SK. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005;54:765-9.
155. Srinivasan M, Irving BA, Dhatariya K, Klaus KA, Hartman SJ, McConnell JP, et al. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. J Clin Endocrinol Metab. 2009;94:761-4.
156. Coles AJ, Thompson S, Cox AL, Curran S, Gurnell EM, Chatterjee VK. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. Eur J Immunol. 2005;35:3694-703.
157. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275:104-15.
158. Saag KG, Furst DE. Major side effects of systemic glucocorticoids. UpToDate. 2013.
159. Li Voon Chong JS, Sen J, Johnson Z, Kyle G, MacFarlane IA. Hydrocortisone replacement dosage influences intraocular pressure in patients with primary and secondary hypocortisolism. Clin Endocrinol (Oxf). 2001;54:267-71.
160. Alves C, Robazzi TC, Mendoça M. Withdrawal from glucocorticosteroid Therapy: clinical practice recommendations. J Pediatr. 2008;84:192-202.
161. White K, Arlt W. Adrenal crisis in treated Addison's disease: a predictable but under-managed event. Eur J Endocrinol. 2010;162:115-20.
162. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol. 2010;162:597-602.
163. Stewart PM. The adrenal cortex. En: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Textbook of Endocrinology. Philadelphia: Saunders; 2009. p. 486-94.
164. Lewandowski K, Hincz, P, Grzesiak M, Cajdler-Luba A, Salata I, Wilczynski J, et al. New onset Addison's disease presenting as prolonged hyperemesis in early pregnancy. Ginekol Pol. 2010; 81:537-40.
165. Gradden C, Lawrence D, Doyle PM, Welch CR. Uses of error: Addison's disease in pregnancy. Lancet. 2001:357:1197.
166. Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev. 2005;26:775-99.
167. Jung C, Ho JT, Torpy DJ, Rogers A, Doogue M, Lewis JG, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-40.
168. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin. Endocrinol (Oxf). 2013;78:497-502.
169. Yuen KC, Chong LE, Koch CA. Adrenal insufficiency in pregnancy: challenging issues in diagnosis and management. Endocrine. 2013;44:283-92.
170. Ambrosi B, Barbetta L, Morricone L. Diagnosis and management of Addison's disease during pregnancy. J Endocrinol Invest. 2003;26:698-702.
171. Siddiqi SS, Singh SK, Khan SA, Ishtiaq O, Pathan MF, Raza SA, et al. Guidelines regarding management of adrenal insufficiency in the Holy month of Ramadan. Indian. J Endocrinol Metab. 2012;16:519-21.